an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
Published 2 weeks ago • 75 plays • Length 4:02Download video MP4
Download video MP3
Similar videos
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:01
considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
1:27
the value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
-
2:08
mcla-128: a her2xher3 bispecific antibody with a novel dock & block® | mechanism of action (moa)
-
3:36
bite® immunotherapy: the next generation of cancer treatment
-
3:19
bispecific antibody
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:56
bfcr4350a: a novel bispecific antibody in r/r myeloma therapy
-
1:23
investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
2:00
the success story of bispecific and trispecific antibodies
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:56
the exciting future of bispecific antibodies
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
3:28
a phase ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myeloma
-
3:44
bispecific antibodies in b-all; blinatumomab
-
1:36
bispecific antibodies for r/r aml: ongoing clinical trials
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml